PSME2 and non-small cell lung carcinoma: The results showed that among 2166 NSCLC patients in the public database, the group with low expression of PSME2, CD137, VGF, B2M and HSP90AB1 was associated with better OS, and the hazard ratio (HR) was greater than 1 (Figures 2A–E; P < 0.05), and among 704 patients with negative surgical margins, the low LMP2 expression group had a better survival benefit than the high LMP2 expression group, and the HR was greater than 1 (Figure 2F; P < 0.05).